Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Sinopharm Group Co ( (HK:1099) ) is now available.
Sinopharm Group Co. Ltd. has announced its unaudited financial results for the nine months ending September 30, 2025, in compliance with the PRC GAAP. The company’s consolidated financial statements reveal a total asset increase to RMB 418.38 billion, indicating a robust financial position despite a decrease in cash at bank and on hand. This financial disclosure is crucial for stakeholders as it reflects the company’s operational performance and financial health, impacting its market positioning and investor confidence.
The most recent analyst rating on (HK:1099) stock is a Buy with a HK$21.00 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
More about Sinopharm Group Co
Sinopharm Group Co. Ltd. is a joint stock limited company incorporated in the People’s Republic of China, operating in the pharmaceutical industry. It provides a range of healthcare products and services, focusing on the distribution and retail of pharmaceutical products, medical devices, and healthcare services.
YTD Price Performance: -4.44%
Average Trading Volume: 5,478,128
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$61.03B
Learn more about 1099 stock on TipRanks’ Stock Analysis page.